-
Despite Erroneous Report, Gene Therapy Trial Will Continue
An adverse event report was erroneously submitted in Sarepta Therapeutics’ trial of experimental DMD therapy, but the trial was allowed to continue. Read the full story here.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.